EPO treatment has been investigated in human studies in psychiatric disorders such as treatment-resistant depression, bipolar disorder, and schizophrenia and in an animal model of autism spectrum disorder (Miskowiak et al. 2014; Ott et al. 2016; Petersen et al. 2018; Solmaz et al. 2020). The gene discussed is EPO; the disease is depressive disorder.